[1]
|
Livingstone C. IGF2 and cancer[J]. Endocr Relat Cancer, 2013, 20: R321-R339. |
[2]
|
Pegtel DM, Gould SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514. doi: 10.1146/annurev-biochem-013118-111902 |
[3]
|
Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update[J]. World J Urol, 2020, 38: 1895-904. doi: 10.1007/s00345-019-02984-4 |
[4]
|
Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin[J]. Eur Urol, 2016, 69: 60-69. doi: 10.1016/j.eururo.2015.06.045 |
[5]
|
Yafi FA, Brimo F, Auger M, et al. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer[J]. Urol Oncol, 2014, 32: 27. e1-e6. doi: 10.1016/j.urolonc.2012.09.011 |
[6]
|
李腾林, 张焕涛, 陆身修, 等. 尿肿瘤标志物联合检测在膀胱癌早期诊断中的应用价值[J]. 中外医学研究, 2021, 19: 80-82. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY202109030.htm
Li TL, Zhang HT, Lu SX, et al. Application Value of Combined Detection of Urinary Tumor Markers in the Early Diagnosis of Bladder Cancer[J]. Zhongwai Yixue Yanjiu, 2021, 19: 80-82. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY202109030.htm |
[7]
|
Bobrie A, Colombo M, Krumeich S, et al. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation[J]. J Extracell Vesicles, 2012. doi: 10.3402/jev.v1i0.18397. |
[8]
|
Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871: 455-468. doi: 10.1016/j.bbcan.2019.04.004 |
[9]
|
Vennin C, Spruyt N, Robin YM, et al. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications[J]. Cancer Lett, 2017, 385: 198-206. doi: 10.1016/j.canlet.2016.10.023 |
[10]
|
Dong Y, Li J, Han F, et al. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer[J]. Oncol Rep, 2015, 34: 936-942. doi: 10.3892/or.2015.4048 |
[11]
|
Weischenfeldt J, Dubash T, Drainas AP, et al. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking[J]. Nat Genet, 2017, 49: 65-74. https://www.nature.com/articles/ng.3722/ |
[12]
|
Vidal SJ, Rodriguez-Bravo V, Quinn SA, et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer[J]. Cancer Cell, 2015, 27: 223-239. doi: 10.1016/j.ccell.2014.11.013 |
[13]
|
Watson JA, Burling K, Fitzpatrick P, et al. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder[J]. BJU Int, 2009, 103: 694-697. doi: 10.1111/j.1464-410X.2008.08213.x |
[14]
|
Ribal MJ, Mengual L, Lozano JJ, et al. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study[J]. Eur J Cancer, 2016, 54: 131-138. doi: 10.1016/j.ejca.2015.11.003 |